CLARET-CAPITAL-PARTNERS
29.10.2020 12:41:03 CET | Business Wire | Press release
Harbert Management Corporation (“HMC”) and Claret Capital Partners Limited (“Claret”), a company formed by David Bateman and Johan Kampe, are pleased to announce the closing of a transaction by which Claret has assumed full ownership and control of the general partners of Harbert European Growth Capital (“HEGC”) investment funds, including Harbert European Growth Capital Fund I, L.P. (“HEGCF I”), Harbert European Growth Capital Fund II, SCSp (“HEGCF II”) and the newly launched Harbert / Claret European Growth Capital Fund III, SCSp (“HEGCF III”). HMC and its affiliates will remain investors in HEGCF I and HEGCF II, and HMC’s interests continue to be aligned with investors in HEGCF I and HEGCF II.
In connection with the transaction, Claret is hiring the entire HEGC investment team, assuming the lease for their current office space in London and acquiring related assets from HMC. Johan Kampe, Managing Partner of Claret, said “Over the past seven years, we have built a fantastic team of investment professionals who have proven to be outstanding stewards of the capital invested through HEGCF I and HEGCF II. This investment team will remain the same, and their activities are expected to continue seamlessly as we commence investing HEGCF III.”
As a result of the transaction, Claret now manages, or has arranged for the third party management of, the HEGC funds commencing October 26, 2020. While HMC no longer serves as the investment manager for HEGCF I and HEGCF II, HMC will continue to provide operational support and assistance to Claret consistent with past practices pursuant to a services agreement. David Bateman, Managing Partner of Claret, said “We are grateful for our seven year partnership with HMC, during which time we learned a great deal about managing investment funds. This experience has prepared us well to take the next step in the evolution of the HEGC strategy and consolidate investment and operational functions within Claret, of course working with our chosen third party managers, and with the continuing support of HMC. We are very excited to be taking this step.”
HMC and the principals of Claret formed HEGCF I in partnership together in 2013, and over the past seven years have built one of the preeminent providers of venture and growth debt to SMEs in Europe, with over €400 million invested in over 120 European SMEs and recognition as Investor All Stars – 2019 Specialty Debt Provider of the Year. Raymond Harbert, Chief Executive Officer of HMC, said “As we look back over the last seven years, we are proud of what we have accomplished together with the Harbert European Growth Capital strategy, and we remain very pleased with our investments in the HEGC funds. However, as I look forward into the future, it is clear to me that the time is right for David and Johan to take this strategy into the future from Europe, independent of HMC, but with HMC’s full support.”
For More Information
Visit: www.claret-capital.com
###
View source version on businesswire.com: https://www.businesswire.com/news/home/20201029005642/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Estithmar Holding Pays the Third Semi-Annual coupon of the 8.75% Sukuk Tranche12.3.2026 21:50:00 CET | Press release
Estithmar Holding Q.P.S.C. has paid the third semi-annual coupon of its Qatari Riyal-denominated Sukuk (first tranche), at an annual profit rate of 8.75%. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260312880092/en/ Estithmar Holding Pays the Third Semi-Annual coupon of the 8.75% Sukuk Tranche (Photo: AETOSWire) The first tranche, part of the company’s broader Sukuk program valued at QAR 3.4 billion and listed on the London Stock Exchange’s International Securities Market, was issued in August 2024. The issuance attracted a diverse pool of institutional investors including banks, insurance companies, and asset managers, with strong interest from both government-affiliated and private institutions. This demand reflects growing investor confidence in Estithmar Holding’s ability to deliver sustained value to stakeholders. EstithmarHolding was recently included in the FTSE Russell Global Equity Index, in Qatar’s Mid-Cap segme
Andersen Consulting styrker sine kompetencer i samarbejde med Acumen Learning12.3.2026 21:36:00 CET | Pressemeddelelse
Andersen Consulting udvider sin platform gennem en samarbejdsaftale med Acumen Learning, en amerikansk virksomhed, der specialiserer sig i træning i forretnings- og økonomiforståelse med henblik på lederudvikling og salgsresultater. Acumen Learning blev stiftet i 2002 og samarbejder med Fortune 500-virksomheder for en bedre finansiel forståelse, strategisk tænkning og beslutningstagning på alle niveauer. Med udgangspunkt i principperne fra deres bestsellerbøger "Seeing the Big Picture" og "Business Acumen for Sales Success" klæder deres programmer ledere og teams på til at afstemme beslutninger med virksomhedsstrategier, fremme resultater og styrke kunderelationer. Acumen Learning er målrettet brancher som sundhedssektoren, energi og teknologi og giver fagfolk mulighed for at omsætte forretningsviden til håndgribelige resultater. "Hos Acumen Learning er vores mission at styrke det enkelte menneske ved at skabe forretningskyndige fagfolk, der gør en forskel i deres karrierer," udtalte K
REPLY: The Board of Directors Approved the Draft Financial Statements for the Year 202512.3.2026 15:38:00 CET | Press release
All economic indicators are positive.Consolidated turnover of €2,483.6 million (€2,300.5 million in 2024);EBITDA at €467.6 million (€410.6 million in 2024);EBIT at €391.7 million (€330.4 million in 2024)Group net profit at €250.9 million (€211.1 million in 2024)Approval of the proposed dividend distribution of €1.35 per share. Today the Board of Directors of Reply S.p.A. [MTA, STAR: REY] approved the draft financial statement for the year 2025, which will be submitted for approval to the Shareholders’ Meeting to be held in first call in Turin on 23 April 2026. The Reply Group closed 2025 with a consolidated turnover of €2,483.6 million, an increase of 8.0% compared to €2,300.5 million in 2024. All indicators are positive for the period. Consolidated EBITDA was €467.6 million, an increase of 13.9% compared to €410.6 million at December 2024. EBIT, from January to December, was at €391.7 million, which is an increase of 18.5% compared to €330.4 million at December 2024. The Group net pro
LZE GmbH Introduces Fraunhofer’s RFicient® Technology to the Market12.3.2026 14:51:00 CET | Press release
LZE GmbH is expanding its technology transfer portfolio and making the RFicient® ultra-low-power wake-up receiver technology from the Fraunhofer Institute for Integrated Circuits IIS available for the first time as a standard chip for close-to-production industrial applications. The solution enables energy-efficient IoT designs that remain continuously reachable while consuming only microamps – a key step for long-lasting, low-maintenance IoT products. LZE GmbH drives technology transfer to market: standard chip availability for close-to-production applications As a bridge between research and industry, LZE GmbH is making it easier for companies to access innovative technologies and helping them to quickly and reliably transform new developments into market-ready solutions. With RFicient®-IC (FH101RF), LZE is providing another high-tech product that comes directly from Fraunhofer research and can now be ordered in volume and integrated into close-to-production product development for t
Owkin Creates New Spin out Waiv, Formerly Owkin Dx, With $33M Financing12.3.2026 14:30:00 CET | Press release
Investment lead by OTB Ventures and Alpha Intelligence CapitalWaiv develops AI-powered precision testing to better identify and stratify patients in the clinic and in clinical trials, transforming patient careWaiv extends Owkin’s strategy of real-world validation for its AI Owkin, the AI company on a mission to solve the complexity of biology, today announced the spin out of Waiv, formerly known as Owkin Dx. The move follows significant investor interest and positions Waiv to bring AI-powered precision testing for better identification of patients in the clinic and in clinical trials, to transform patient care. This follows on from the successful launch of Bioptimus, an Owkin incubated company, in February 2024. Waiv translates AI innovation into real-world clinical impact, developing tests that predict biomarkers and patient outcomes, including RlapsRisk BC for prognostic risk profiling. With multiple tests already in use in clinical settings, its deployment platform Destra, and colla
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
